ME News reports that on September 23 (UTC+8), Viking Therapeutics Inc.'s stock surged significantly after the company announced positive results from a small exploratory study showing that its dual-target injectable obesity drug helped patients achieve weight loss and maintain those results even after reducing dosing frequency. The company drew conclusions based on data from patients in the study’s expansion cohort. The initial phase of the study aimed to identify the most effective dose of a drug that controls weight through two distinct pathways. These findings are encouraging for Viking, which had previously faced setbacks in earlier trials. The company reported that patients receiving a moderate weekly dose during the main trial phase achieved the best results, losing up to 19% of their body weight after approximately five months. An “exploratory” group of 13 patients continued receiving a slightly lower dose for an additional three months, achieving a 22% weight loss without reaching a plateau. Viking noted that some patients maintained 90% to 97% of their weight loss after transitioning to a lower-frequency dosing regimen (once or twice monthly). Side effects were mostly mild and diminished over time, with only one patient discontinuing treatment due to an adverse event. During the low-frequency maintenance phase, gastrointestinal side effects were comparable to those in the placebo group. Viking’s stock rose as much as 36.6% during intraday trading in New York, marking its largest intraday gain since July 2024, before giving back some of those gains. (Source: BlockBeats)
Viking Therapeutics' obesity drug demonstrates weight loss maintenance; shares rise 36.6%
KuCoinFlashShare
Summary
Viking Therapeutics' obesity drug demonstrated sustained weight loss in a small trial, sending shares up 36.6% on September 23, 2026. Patients lost up to 19% of their body weight within five months, with some maintaining 90–97% of that loss on reduced doses. On-chain data indicates strong investor sentiment, while on-chain analysis reveals increasing buying pressure. Mild side effects were reported, with no major safety concerns.
Source:Show original
Disclaimer: The information on this page may have been obtained from third parties and does not necessarily reflect the views or opinions of KuCoin. This content is provided for general informational purposes only, without any representation or warranty of any kind, nor shall it be construed as financial or investment advice. KuCoin shall not be liable for any errors or omissions, or for any outcomes resulting from the use of this information.
Investments in digital assets can be risky. Please carefully evaluate the risks of a product and your risk tolerance based on your own financial circumstances. For more information, please refer to our Terms of Use and Risk Disclosure.